Biotech company Rigvir Group, which owns a registered oncolytic virotherapy medicine RIGVIR^® is looking for partners globally to support and finance the commercialization process of a next generation solution for unmet medical needs in oncology based on the existing product.

We have elaborated collaboration model for early Melanoma and Uveal Melanoma treatment – considering the following:

• Medical need – currently no treatment solutions for early both Melanoma and Uveal Melanoma;
• Company owns a unique and well-established treatment method;
• Company owns a GMP API production and know-how;
• RIGVIR^® has Excellent safety profile;
• New projects are supported by preclinical data and retrospective clinical observations;
• The production and use of ECHO7 virus RIGVIR^® have granted strong international IP protection;
• The Company has EMA authorization to start any Phase II clinical trials in the EU.

Information Request